VitaDAO

Overview

VitaDAO is a community-owned collective dedicated to funding and advancing early-stage longevity science research. It was the first DeSci DAO, initiated in July 2021, and has since become the largest in the ecosystem. The organization aims to extend human healthspan and lifespan through accelerated research, open collaboration, and innovative funding structures.

VitaDAO received a landmark $4.1 million investment from Pfizer Ventures in December 2022, marking one of the first major pharmaceutical industry investments in a decentralized science organization. It operates as a BioDAO within the Bio Protocol ecosystem.

Research Portfolio

VitaDAO has funded 31 projects across the drug development pipeline: 3 target discovery projects, 18 drug discovery projects, 3 preclinical drug development projects, and 3 clinical drug development projects. This has generated 8 intellectual property transactions and led to the founding of 3 companies, with a total project fully diluted valuation of $60 million.

The DAO combines human expertise with AI agents — including AubrAI (longevity research specialist), Longevist AI for literature analysis, and a Biohacker Agent for compound formulation — to accelerate discovery in aging research.

External Links

• VitaDAO — Official Website
• VitaDAO Discord
• VitaDAO on X